You are here

Article Text

Article menu
Download PDFPDF
ePoster
EP1210 Follow-up in gynecologic malignancies, correspondence with ESGO Guidelines- preliminary result of ENYGO survey
  1. I Selcuk1,
  2. M Lanner2,
  3. A Pletnev3,
  4. D Vlachos4,
  5. T Nikolova5,
  6. D Lindquist6 and
  7. K Zalewski7
  1. European Network of Young Gynae-Oncologists National Representatives 2017–2019
  2. 1Zekai Tahir Burak Women's Health Training and Research Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey
  3. 2Gynecology and Obstetrics, University Hospital Graz, Graz, Austria
  4. 3Gynecologic Oncology, Alexandrov National Cancer Center of Belarus, Minsk, Belarus
  5. 4Obstetrics and Gynecology, University of Athens, Athens, Greece
  6. 5Obstetrics and Gynecology, University Clinic of Obstetrics and Gynecology, Skopje, The former Yugoslav Republic of Macedomia
  7. 6Medical Oncology, Umeå University Hospital, Umea, Sweden
  8. 7Gynecologic Oncology, Holycross Cancer Center, Kielce, Poland

Abstract

Introduction/Background To identify the follow-up strategies of gynecologic malignancies across Europe and compare the correspondence with ESGO Guidelines.

Methodology In 2019, a web-based survey was sent to the National Representatives of European Network of Young Gynae-Oncologists (2017–2019). The questionnaire consists of the questions related with vulvar cancer, cervical cancer, endometrial cancer and ovarian cancer.

Results A total of 15/31 (48.3%) National Representatives responded the survey. Despite having a national guideline (>50%), the topic of follow-up was missing in some countries. The follow-up was mainly led by clinicians and performed by gynecologic oncology team (table 1). For each malignancy, gynecologic examination is performed at every visit. Responders stated that Pap-test is routinely performed during the follow-up of cervical cancer 8/8 (100.0%), additionally in endometrial cancer 4/7 (57.1%) of responders perform routine Pap-test. Serum Ca-125 level is never routinely preferred during the follow-up of endometrial cancer, however serum Ca-125 is mostly preferred routinely for ovarian cancer. Complete blood count-biochemical tests and chest X-ray are not routine tests to consider at every visit. Routine imaging is mostly preferred for ovarian cancer and computed tomography is the most common imaging technique in case of a suspicion of recurrence except vulvar cancer in which magnetic resonance imaging is preferred (table 2).

Conclusion This preliminary results indicated that follow-up periods are similar with ESGO Guidelines. One of the major differences is that cytology is not recommended after radical/simple hysterectomy or chemoradiation in cervical cancer and the other one is serum Ca-125 is not a reliable marker in non-High grade serous carcinoma of the ovary. ESGO Guidelines generally don't recommend routine imaging unless a clinically indicated situation. Finally, these preliminary results showed that majority of the responses are similar with ESGO Guidelines.

Disclosure Nothing to disclose

View this table:
Abstract EP1210 Table 1

Follow-up methods and periods for vulvar, cervical, endometrial and ovarian cancer

View this table:
Abstract EP1210 Table 2

Performed procedures at every visit for vulvar, cervical, endometrial and ovarian cancer

https://doi.org/10.1136/ijgc-2019-ESGO.1247

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.